What Are the Best Nasdaq Penny Stocks to Invest in?
Nasdaq Penny Stocks are the stocks that are priced under $5 per share. While they may seem like a risky investment, they can offer great potential forhigh returns. However, it is important to do your own research beforeinvestingin any penny stock. Here are some of the best Nasdaq penny stocks to invest in:
1. Zomedica Corp. (ZOM)
Zomedica Corp. is a veterinary diagnostic company that develops and commercializes products for companion animals. They have recently launched their first product, TRUFORMA, which is a diagnostic instrument for veterinarians. The company has seen a lot of interest from investors and has the potential for significant growth in the coming years.
2. Cinedigm Corp. (CIDM)
Cinedigm Corp. is a distributor of independent films and television shows. The company has recently announced a new partnership with Kanopy, a streaming service for public libraries and universities. This partnership is expected to bring in significant revenue for Cinedigm and could result in a rise in stock prices.
3. Genius Brands International Inc. (GNUS)
Genius Brands International Inc. is a children's media company that creates and licenses animated content. The company has recently launched their own streaming service, Kartoon Channel!, which has seen a lot of success. They have also announced partnerships with major companies such as Amazon, Netflix, and Disney.
4. T2 Biosystems Inc. (TTOO)
T2 Biosystems Inc. is a medical technology company that focuses on developing diagnostic tests for infectious diseases. The company has recently received FDA clearance for their COVID-19 test, which could result in significant revenue growth. They have also announced partnerships with major healthcare providers.
Investing in Nasdaq penny stocks can be a great way to diversify your portfolio and potentially earn high returns. However, it is important to do your own research and only invest what you can afford to lose. It is also recommended to invest in a variety of stocks to minimize risk.
Article review